Literature DB >> 2984332

Intravenous methylprednisolone for multiple sclerosis in relapse.

M P Barnes, D E Bateman, P G Cleland, D J Dick, T J Walls, P K Newman, M Saunders, P J Tilley.   

Abstract

A randomised comparison is made between methylprednisolone, 1 g intravenously daily for 7 days, and a standard ACTH regime for the treatment of multiple sclerosis in acute relapse. It is found that methylprednisolone produces a more rapid clinical improvement than ACTH but confers no longer term benefit when the two treatments are compared at 3 months. It is proposed that intravenous methylprednisolone does have a role to play in the management of a patient with an acute relapse of multiple sclerosis.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2984332      PMCID： PMC1028218          DOI： 10.1136/jnnp.48.2.157

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  6 in total

1.  FURTHER NOTES ON DISABILITY EVALUATION IN MULTIPLE SCLEROSIS, WITH SCALE MODIFICATIONS.

Authors:  J F KURTZKE
Journal:  Neurology       Date:  1965-07       Impact factor: 9.910

2.  Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo--final report.

Authors:  A S Rose; J W Kuzma; J F Kurtzke; N S Namerow; W A Sibley; W W Tourtellotte
Journal:  Neurology       Date:  1970-05       Impact factor: 9.910

3.  Long-term treatment of multiple sclerosis with corticotrophin.

Authors:  J H Millar; C J Vas; M J Noronha; L A Liversedge; M D Rawson
Journal:  Lancet       Date:  1967-08-26       Impact factor: 79.321

4.  Prolonged effects of large-dose methylprednisolone infusion in multiple sclerosis.

Authors:  J L Trotter; W F Garvey
Journal:  Neurology       Date:  1980-07       Impact factor: 9.910

5.  Treatment of acute exacerbations of multiple sclerosis with intravenous methyl-prednisolone.

Authors:  C Buckley; C Kennard; M Swash
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-02       Impact factor: 10.154

6.  Possible beneficial effect of high-dose intravenous steroid therapy in acute demyelinating disease and transverse myelitis.

Authors:  P C Dowling; V V Bosch; S D Cook
Journal:  Neurology       Date:  1980-07       Impact factor: 9.910
  6 in total
  22 in total

1.  A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy.

Authors:  Pietro Annovazzi; Valentina Tomassini; Benedetta Bodini; Laura Boffa; Massimiliano Calabrese; Eleonora Cocco; Cinzia Cordioli; Giovanna De Luca; Giovanni Frisullo; Antonio Gallo; Simona Malucchi; Damiano Paolicelli; Ilaria Pesci; Marta Radaelli; Paolo Ragonese; Luca Roccatagliata; Carla Tortorella; Marco Vercellino; Valentina Zipoli; Claudio Gasperini; Mariaemma Rodegher; Claudio Solaro
Journal:  Neurol Sci       Date:  2012-03-11       Impact factor: 3.307

2.  Assessing relapses and response to relapse treatment in patients with multiple sclerosis: a nursing perspective.

Authors:  Amy Perrin Ross; June Halper; Colleen J Harris
Journal:  Int J MS Care       Date:  2012

3.  Immunological treatment of multiple sclerosis. II.

Authors:  R A Hughes
Journal:  J Neurol       Date:  1986-04       Impact factor: 4.849

4.  Methylprednisolone in multiple sclerosis: a comparative dose study.

Authors:  L Bindoff; P R Lyons; P K Newman; M Saunders
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-08       Impact factor: 10.154

5.  Quantitative magnetic resonance imaging in multiple sclerosis: the effect of high dose intravenous methylprednisolone.

Authors:  J Kesselring; D H Miller; D G MacManus; G Johnson; N M Milligan; N Scolding; D A Compston; W I McDonald
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-01       Impact factor: 10.154

Review 6.  Treatment of acute relapses in multiple sclerosis.

Authors:  Regina Berkovich
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

7.  Short-term high dose steroid therapy does not affect the hypothalamic-pituitary-adrenal axis in relapsing multiple sclerosis patients. Clinical assessment by the insulin tolerance test.

Authors:  Z Lević; D Micić; J Nikolić; N Stojisavljević; D Sokić; S Janković; A Kendereski; M Mavra
Journal:  J Endocrinol Invest       Date:  1996-01       Impact factor: 4.256

Review 8.  Newer versus older treatments for relapsing-remitting multiple sclerosis.

Authors:  B Weinstock-Guttman; J A Cohen
Journal:  Drug Saf       Date:  1996-02       Impact factor: 5.606

Review 9.  Clinical experience with repository corticotropin injection in patients with multiple sclerosis experiencing mood changes with intravenous methylprednisolone: a case series.

Authors:  Stacey Murray; Andrew Woo
Journal:  Ther Adv Neurol Disord       Date:  2015-12-07       Impact factor: 6.570

10.  Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose.

Authors:  S M Alam; T Kyriakides; M Lawden; P K Newman
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-11       Impact factor: 10.154
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.